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Sonic Hedgehog-Induced Functional Recovery
After Myocardial Infarction Is Enhanced by
AMD3100-Mediated Progenitor-Cell Mobilization
Jérôme Roncalli, MD, PHD,*† Marie-Ange Renault, PHD,* Jörn Tongers, MD,*‡ Sol Misener, AAS,*
Tina Thorne, MS,* Christine Kamide, BS,* Kentaro Jujo, MD,* Toshikazu Tanaka, MD,*
Masaaki Ii, MD, PHD,§ Ekaterina Klyachko, PHD,* Douglas W. Losordo, MD*
Chicago, Illinois; Toulouse, France; Hannover, Germany; and Kobe, Japan
Objectives This study was designed to compare the effectiveness of Sonic hedgehog (Shh) gene transfer, AMD3100-
induced progenitor-cell mobilization, and Shh-AMD3100 combination therapy for treatment of surgically induced
myocardial infarction (MI) in mice.
Background Shh gene transfer improves myocardial recovery by up-regulating angiogenic genes and enhancing the incorpo-
ration of bone marrow–derived progenitor cells (BMPCs) in infarcted myocardium. Here, we investigated whether
the effectiveness of Shh gene therapy could be improved with AMD3100-induced progenitor-cell mobilization.
Methods Gene expression and cell function were evaluated in cells cultured with medium collected from fibroblasts trans-
fected with plasmids encoding human Shh (phShh). MI was induced in wild-type mice, in matrix metalloprotei-
nase (MMP)-9 knockout mice, and in mice transplanted with bone marrow that expressed green-fluorescent pro-
tein. Mice were treated with 100 g of phShh (administered intramyocardially), 5 mg/kg of AMD3100
(administered subcutaneously), or both; cardiac function was evaluated echocardiographically, and fibrosis, cap-
illary density, and BMPC incorporation were evaluated immunohistochemically.
Results phShh increased vascular endothelial growth factor and stromal cell–derived factor 1 expression in fibroblasts;
the medium from phShh-transfected fibroblasts increased endothelial-cell migration and the migration, prolifera-
tion, and tube formation of BMPCs. Combination therapy enhanced cardiac functional recovery (i.e., left ventricu-
lar ejection fraction) in wild-type mice, but not in MMP-9 knockout mice, and was associated with less fibrosis,
greater capillary density and smooth muscle–containing vessel density, and enhanced BMPC incorporation.
Conclusions Combination therapy consisting of intramyocardial Shh gene transfer and AMD3100-induced progenitor-cell mo-
bilization improves cardiac functional recovery after MI and is superior to either individual treatment for promot-
ing therapeutic neovascularization. (J Am Coll Cardiol 2011;57:2444–52) © 2011 by the American College of
Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2010.11.069b
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(Recent investigations suggest that the effectiveness of an-
giogenic gene therapy may be increased by combining it
with treatments that mobilize progenitor cells from the
bone marrow. Kawamoto et al. (1) combined gene transfer
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2010, accepted November 23, 2010.of vascular endothelial growth factor (VEGF) with
progenitor-cell mobilization in animal models of acute and
chronic myocardial infarction, revealing that the combina-
tion therapy was more effective than either treatment alone.
However, these promising results were not reproduced in a
phase I clinical study that combined intramyocardial injec-
tion of VEGF-A plasmid and progenitor-cell mobilization
in patients with severe chronic ischemic heart disease (2);
oth of these investigations mobilized stem cells via the
dministration of granulocyte colony-stimulating factor,
hich has been associated with an increased risk of reste-
osis in 1 report (3).
Previously we demonstrated that myocardial infarction
MI) reactivates the Hedgehog signaling pathway in adult
ammals and that Sonic hedgehog (Shh) up-regulates the
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June 14, 2011:2444–52 Cell Mobilization Enhances Sonic Hedgehog Therapy for MIexpression of several angiogenic and cardioprotective genes,
including VEGF. Consequently, the vascular benefits of
Shh gene therapy may be more robust and extensive than
those observed with VEGF alone. Shh gene transfer also
preserved left ventricular function, reduced fibrosis, in-
creased angiogenesis, and enhanced the contribution of
bone marrow–derived progenitor cells (BMPCs) to myo-
cardial neovascularization in animal models of acute and
chronic MI (4).
Because Shh gene therapy appears to improve recovery
from MI, at least in part, by increasing the incorporation of
BMPCs, it may be particularly effective when administered
with treatments that increase progenitor-cell mobilization.
We tested this hypothesis in a murine model of MI by
combining myocardial injection of a plasmid encoding the
human Shh gene (phShh) with subcutaneous injections of
AMD3100, a pharmacological agent that mobilizes progen-
itor cells by disrupting interactions between CXC-
chemokine receptor 4 (CXCR4) and stromal cell–derived
factor (SDF)-1. Our findings indicate that combined ther-
apy improves cardiac functional recovery after MI and more
effectively promotes neovascularization than either individ-
ual treatment.
Methods
Experimental reagents. AMD3100 was purchased from
igma-Aldrich Co. (St. Louis, Missouri), and Shh protein
as provided by William Munger, PhD, of Curis Inc.
Lexington, Massachusetts). The phShh was prepared as
escribed previously (4) and as summarized in the Online
ppendix.
ell lines and media. In vitro experiments were performed
ith National Institutes of Health 3T3 fibroblasts (ATCC,
anassas, Virginia), bovine aortic endothelial cells (ATCC),
nd BMPCs. BMPCs were isolated from the total mononu-
lear cell population (5,6); mononuclear cells were obtained
rom mouse tibias and femurs by density gradient selection,
lated on culture dishes coated with rat vitronectin, and
ultured in endothelial-growth medium; nonadherent cells
ere discarded. Procedures for cell maintenance and transfec-
ion, collection of the Shh-conditioned and control media, and
MPC isolation and expansion are summarized in the Online
ppendix.
ell functional assays. Migration, proliferation, and tube
ormation were assessed via standardized protocols as sum-
arized in the Online Appendix. Assessments were per-
ormed by personnel who were blinded to treatment.
ouse lines. All experimental procedures were approved
y the Institutional Animal Care and Use Committee of
orthwestern University. MI was surgically induced in 8-
o 10-week-old wild-type C57BL/6J mice (The Jackson
aboratory, Bar Harbor, Maine), wild-type (Charles River
aboratories International, Inc., Wilmington, Massachu-
etts) and matrix metalloproteinase (MMP)-9 knockout
The Jackson Laboratory) FVB mice, and in wild-type SC57BL/6J mice transplanted with
bone marrow from age- and sex-
matched green-fluorescent protein
(GFP)-expressing C57BL/6-
Tg(ACTB-EGFP)1Osb/J mice
(The Jackson Laboratory). Bone
marrow transplantation was per-
formed as described previously (1)
and as summarized in the Online
Appendix.
Surgical induction of MI and
treatment. MI was induced as
described in the Online Appen-
dix. Ten minutes later, 0.02 ml of
sterile saline containing 100 g of
ither phShh or the empty plasmid
as injected into 2 sites within the
egion perfused by the left anterior
escending artery; the injection
ites were located at the border
one of the infarct, as indicated by
hanges in the color of the myo-
ardium after left anterior descending artery ligation.
MD3100 (5 mg/kg) was administered subcutaneously ap-
roximately 1 h after MI surgery. Subsequent analyses were
erformed by personnel who were blinded to treatment.
chocardiographic assessment of cardiac function. Left
entricular ejection fractions (LVEFs) were calculated from
chocardiographic measurements performed before MI and
 1 days, 14  1 days, and 28  2 days afterward. The
chocardiographic protocol is summarized in the Online
ppendix.
istology and immunology. Histological and immuno-
ogic assessments are summarized in the Online Appendix.
ibrosis was reported as the ratio of the area of fibrosis to
he left-ventricular area. Capillaries were identified by
ither: 1) injecting mice with fluorescein isothiocyanate–
abeled BS1-lectin (Vector Laboratories, Burlingame, Cal-
fornia) 10 min before sacrifice; or 2) staining tissue sections
ith fluorescein isothiocyanate–labeled isolectin B4.
mooth muscle–containing vessels were identified as tubu-
ar structures stained positively for smooth-muscle  actin
nd isolectin B4 or smooth-muscle  actin and BS1-lectin.
MP-9–expressing cells were identified by staining sec-
ions with anti–MMP-9 antibodies. Bone marrow–derived
ells were identified by staining tissue sections with anti-
FP antibodies rather than via intrinsic GFP expression,
ecause GFP fluorescence is low after bone marrow trans-
lantation, and the infarcted tissue autofluoresces.
uantitative reverse transcriptase polymerase chain reaction.
uantitative reverse transcriptase polymerase chain reaction
as performed via standardized protocols as summarized in
he Online Appendix; primer and probe sequences are
eported in Online Table 1.
tatistical analysis. All values were expressed as mean 
Abbreviations
and Acronyms
BMPC  bone marrow–
derived progenitor cell
CXCR4  CXC-chemokine
receptor 4
G-CSF  granulocyte
colony-stimulating factor
LVEF  left ventricular
ejection fraction
MI  myocardial infarction
MMP  matrix
metalloproteinase
phShh  plasmid encoding
the human Shh gene
SDF  stromal cell–derived
factor
Shh  Sonic hedgehog
VEGF  vascular
endothelial growth factorEM, and a p value 0.05 was considered statistically
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significance was evaluated with the unpaired t test. Com-
parisons among 3 or 4 groups were assessed via 1-factor
analysis of variance followed by the Fisher protected least
significant difference post-hoc test when analysis of variance
p  0.05. The relationship between LVEF and capillary
density was tested via linear regression. In vitro conditions
were evaluated in triplicate (or higher replicates), and data
points were used as the unit of analysis; each experiment was
performed at least twice. Additional details are provided in
the Online Appendix.
Results
Human Shh activates the hedgehog pathway in fibroblasts
and induces secretion of VEGF and SDF-1. The mRNA
expression of hShh, the Hedghog receptor Patched-1, and
Gli1 (a transcription factor targeted by Hedgehog signaling)
was significantly greater (p  0.05) in mouse 3T3 fibro-
blasts transfected with phShh than in fibroblasts transfected
with the empty vector for up to 5 days after transfection
(Online Figs. 1A to 1C); maximum hShh expression was
observed 48 h after transfection, whereas Patched-1 and
Gli1 expression peaked at 72 h. Plasmid hShh gene therapy
was also associated with a 5-fold up-regulation of VEGF-A
mRNA expression (p  0.01) and a 2-fold up-regulation of
SDF-1 mRNA expression (p  0.01) at 48 h (Online
igs. 1D and 1E). Supernatant levels of VEGF and
DF-1 protein were quantified 72 h after transfection;
VEGF (p  0.0001) and SDF-1 (p  0.01) protein levels
ere significantly higher in supernatants collected from
hShh-transfected cells than from cells transfected with the
mpty vector (Online Figs. 1F and 1G). Incubation with
Shh protein (1 g/ml) for 24 h also led to higher
upernatant levels of VEGF (p 0.0001) and SDF-1 (p
0.0001) (Online Figs. 1H and 1I).
Shh-conditioned medium promotes capillary morphogenesis,
proliferation, and migration in BMPCs and endothelial cells.
The migration of both BMPCs (p  0.001) and bovine
aortic endothelial cells (p  0.01) was significantly greater
in cells treated with Shh-conditioned medium (i.e., super-
natants collected from phShh-transfected fibroblasts) than
with unconditioned medium (i.e., supernatants collected
from fibroblasts transfected with an empty vector) (Figs. 1A
and 1B), and Shh-conditioned medium also enhanced
proliferation (p  0.01) (Figs. 1C and 1D) and tube
formation (p  0.05) (Figs. 1E and 1F) in BMPCs.
Combination therapy enhances the recovery of cardiac
function after MI. One day after surgically induced MI,
Shh expression was approximately 200-fold greater in mice
administered phShh gene therapy alone (100 mg/mouse) or
combination therapy consisting of both phShh administra-
tion and AMD3100 (5 mg/kg) than in mice treated with
AMD3100 alone or in untreated and control mice (p 
0.0001); the differences between groups remained statisti-cally significant on day 5 (p  0.05) (Fig. 2A). SDF-1
mRNA expression was similar in all groups on day 1 (data
not shown), but on day 5, expression in the infarcted region
and in the border zone of the infarct was significantly
greater in animals administered combination therapy than
in any other treatment group. In noninfarcted tissue,
Figure 1
Shh-Conditioned Medium Promotes
Endothelial-Cell Migration and the Migration,
Proliferation, and Capillary Morphogenesis of BMPCs
(A, B) Migration (*p  0.01), (C, D) proliferation (*p  0.01), and (E, F) tube
formation (*p  0.05) were assessed for bone marrow–derived progenitor
cells (BMPCs) and/or bovine aortic endothelial cells after treatment with con-
trol or Sonic hedgehog (Shh)-conditioned medium. Three independent experi-
ments, n  3 to 5 per condition for each experiment. HPF  high-power field;
OD  optical density.SDF-1 mRNA expression on day 5 was significantly
a
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June 14, 2011:2444–52 Cell Mobilization Enhances Sonic Hedgehog Therapy for MIgreater in the combination therapy group than in animals
treated with phShh alone or in untreated and control
animals (p  0.01) (Fig. 2B).
Cardiac function was evaluated echocardiographically before
MI and 7, 14, and 28 days afterward (Figs. 2C and 2D); the
interaction between time periods and treatment groups was
significant (p  0.0001). Before MI, the mean LVEF for all
nimals was 77 1% (Fig. 2E). LVEF increased between days
and 14 in the combination therapy group and was signifi-
antly greater in animals administered combination therapy
han in untreated animals on day 28 (p 0.05). Improvement
was delayed until after day 14 in animals administered phShh
Figure 2 Combination Therapy Enhances Cardiac Functional Re
Mice were treated with or without plasmid encoding the human Sonic hedgehog ge
induced myocardial infarction (MI); control mice did not undergo surgical MI. (A) C
MI (*p  0.05, **p  0.0001 vs. untreated, AMD3100, and controls). (B) Strom
infarcted, and border-zone regions 5 days after MI (*p  0.05 vs. untreated, AMD
was evaluated via (C, D) echocardiographic assessments of (E) left ventricular eje
ized to endogenous 18S rRNA expression. (A, B) n  3 to 5 per treatment group;alone.Combination therapy reduces cardiac fibrosis and enhances
the development of capillaries and smooth muscle-
containing vessels after MI. In mice sacrificed 28 days after
MI, the extent of fibrosis was significantly lower, and
capillary density was significantly greater, in all treated
groups than in untreated animals (fibrosis, p  0.01;
capillary density, p  0.05) and in the combination
therapy group than in animals administered either indi-
vidual treatment (fibrosis, p  0.05; capillary density, p 
0.05) (Figs. 3A to 3D). When the infarcted region and
border zone were analyzed independently, capillary density
was significantly greater in the infarcted zone of the Shh-
ry After MI
Shh), AMD3100, or phShh-AMD3100 combination therapy after surgically
mRNA expression of the transfected phShh was confirmed 1 and 5 days after
–derived factor 1 (SDF-1) mRNA expression was evaluated in noninfarcted,
and phShh; **p  0.01 vs. untreated and phShh). (C to E) Cardiac function
fractions (LVEFs) (*p  0.013 vs. untreated). mRNA measurements were normal-
 11 to 15 per treatment group.cove
ne (ph
ardiac
al cell
3100,
ction
(E) ntreatment group (p  0.05), in the border zone of the
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Development of Capillaries and Smooth Muscle–Containing Vessels After MI
Mice were sacrificed 28 days after surgically induced MI and treatment with or without phShh, AMD3100, or combination phShh-AMD3100 therapy. (A, B) The proportion of
fibrotic tissue (blue) in the left ventricle was determined by calculating the ratio of the area of fibrosis to the left-ventricular area (*p  0.01 vs. untreated, **p  0.05 vs.
AMD3100 or phShh). (C to H) Sections were stained with (C to F) isolectin B4 and fluorescent anti-isolectin B4 antibodies (green) to identify capillaries or with (G, H) isolectin
B4, fluorescent anti-isolectin B4 antibodies, and anti–smooth-muscle  actin (SMA) (red) antibodies to identify smooth muscle–containing vessels; nuclei were counterstained
with DAPI. Capillary density was evaluated by counting isolectin-B4–positive tubular-like structures (D) in the heart (*p  0.05 vs. untreated, **p  0.05 vs. AMD3100 or
phShh) and in the (E) infarcted (*p  0.05 vs. untreated, †p  0.051 vs. AMD3100) and (F) border-zone regions (*p  0.05 vs. untreated). (H) The density of smooth
muscle–containing vessels was evaluated by counting SMA-positive, isolectin-B4–positive tubular structures (*p  0.05 vs. untreated, **p  0.01 vs. untreated or AMD3100).
n  7 to 10 per treatment group. HPF  high-power field; other abbreviations as in Figure 2.
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gions after treatment with combination therapy (p  0.05)
than in untreated animals (Figs. 3E and 3F). The difference
between the combination therapy and AMD3100 treatment
groups approached significance in the infarcted region (p 
0.051), and a post-hoc analysis indicated that border-zone
capillary density and LVEF on day 28 were correlated (p 
0.05) (Online Fig. 2). Smooth muscle–containing vessels
were significantly more prevalent in animals administered
combination therapy or phShh alone than in untreated
animals (p  0.05) and in the combination therapy group
than in the AMD3100 treatment group (p  0.05) (Figs.
3G and 3H).
Combination therapy enhances the incorporation of
BMPCs. Because SDF-1 is a chemoattractant for BMPCs,
and SDF-1 mRNA expression after MI was significantly
elevated in mice administered combination therapy, we
investigated whether combination therapy increased BMPC
incorporation after MI in wild-type mice transplanted with
bone marrow from GFP-expressing mice. One week after
MI, significantly more bone marrow–derived cells were
identified in the myocardial endothelium of mice from all 3
treatment groups than in untreated mice (p  0.01) and in
Figure 4 Combination Therapy Enhances the Incorporation of B
Wild-type mice transplanted with bone marrow from GFP-expressing mice were sac
AMD3100, or phShh-AMD3100 combination therapy; 10 min before sacrifice on d
binds to endothelial tissue. (A) Bone marrow–derived progenitor cells (BMPCs) we
for BS1-lectin (green) and GFP expression (red GFP-antibody staining); nuclei were
double-positive cells (*p  0.01 vs. untreated, **p  0.001 vs. untreated and si
sectional views of individual vessels from mice treated with combination therapy.
as in Figures 2 and 3.the combination therapy group than in mice administered
either individual treatment (p  0.001) (Figs. 4A and 4B).
The bone marrow–derived cells were primarily incorporated
in the infarcted region and the border zone, and cross-
sectional views of individual vessels also identified vascular
GFP-expressing cells surrounding the endothelium, which
suggests that the neovasculature had matured (Fig. 4C).
MMP-9 contributes to the beneficial effects associated
with combination therapy. One day after MI, MMP-9
mRNA expression was significantly lower in mice admin-
istered AMD3100, both alone and in combination therapy,
than in untreated mice (Fig. 5A); however, expression on
day 5 was significantly higher in the infarcted and border
zone regions of myocardial tissue from mice treated with
combination therapy than in the corresponding regions of
tissues harvested from untreated mice or from mice admin-
istered either individual treatment (p  0.05) (Fig. 5B).
Seven days after MI, MMP-9–positive cells were signifi-
cantly more prevalent in sections from mice in the combi-
nation therapy group than in sections from untreated mice or
from mice administered either individual therapy (Fig. 5C).
To determine whether MMP-9 expression is required for
the enhanced cardiac functional recovery observed in mice
s
28 days after surgically induced MI and treatment with or without phShh,
mice were injected with fluorescein isothiocyanate–conjugated BS1-lectin, which
ntified in the myocardial endothelium via double-positive staining (yellow-orange)
er-stained with DAPI (blue). (B) BMPC incorporation was evaluated by counting
erapies). (C) Endothelial tissue (green) and BMPCs (red) are identified in cross-
to 5 per treatment group. GFPab  GFP antibody staining; other abbreviationsMPC
rificed
ay 28,
re ide
count
ngle th
n  4
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wild-type and MMP-9 knockout mice before MI and 7, 14,
and 28 days afterward (Fig. 5D). Twenty-eight days after
MI, LVEFs were significantly lower in MMP-9 knockout
mice treated with combination therapy than in wild-type
mice treated with combination therapy. Collectively, these
observations indicate that MMP-9 expression contributes to
the beneficial effects associated with combination therapy
after MI.
Discussion
To date, studies of cardiovascular regeneration have primar-
ily investigated gene therapy (7) and cell mobilization (8)
independently. However, the promising pre-clinical results
Figure 5 MMP-9 Expression After MI Is Enhanced by Combinat
and the Benefit of Combination Therapy Is Impaired in
(A) One day and (B) 5 days after surgical induction of MI and treatment with or w
teinase 9 (MMP-9) mRNA expression was measured in the noninfarcted, infarcted
untreated). (C) MMP-9 protein expression was summarized by counting MMP-9–po
were measured before MI and 7, 14, and 28 days afterward in wild-type FVB and M
apy (*p  0.05 vs. MMP-9 knockout with combination therapy). mRNA measureme
treatment group; (D) n  7 to 9 per treatment group. Abbreviations as in Figuresachieved with each individual treatment have not beenadequately reproduced in clinical studies. Although this
discrepancy may be partly caused by issues in trial design, we
considered whether a combination of approaches could be
superior to monotherapy. Because gene therapy is more
practical for treating patients who develop myocardial dys-
function after MI than for preventing myocardial reperfu-
sion injury in patients experiencing an acute cardiac event,
we induced MI by permanently ligating the coronary artery,
rather than by temporarily restricting blood flow via coro-
nary banding. Furthermore, we mimicked one form of
clinical gene delivery (e.g., via the NOGA system, Biosense
Webster, Diamond Bar, California) (9) by administering
phShh directly to the myocardium. Our results demonstrate
that Shh gene therapy and AMD3100-stimulated
herapy,
P-9 Knockout Mice
phShh, AMD3100, or phShh-AMD3100 combination therapy, matrix metallopro-
order-zone regions; control mice did not undergo surgical MI (*p  0.05 vs.
cells (*p  0.01 vs. untreated, **p  0.05 vs. AMD3100 or phShh). (D) LVEFs
knockout FVB mice treated with or without phShh-AMD3100 combination ther-
ere normalized to endogenous 18S rRNA expression. (A to C) n  3 to 5 per
3.ion T
MM
ithout
, and b
sitive
MP-9
nts w
2 andprogenitor-cell mobilization reduced cardiac fibrosis and
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June 14, 2011:2444–52 Cell Mobilization Enhances Sonic Hedgehog Therapy for MIpromoted the development of capillaries and smooth
muscle–containing vessels after MI more effectively when
combined than when either treatment was administered
individually. Furthermore, LVEF measurements were sig-
nificantly greater in the combination therapy group than in
untreated mice, and cardiac functional recovery was more
rapid after combination therapy than gene therapy alone,
which may improve efficacy and alleviate some of the safety
concerns associated with gene therapy (10).
Previously, members of our lab have investigated therapy
that combined local VEGF signaling with the cell-
mobilizing agent granulocyte colony-stimulating factor (G-
CSF) (1). The VEGF–G-CSF combination, like the
phShh-AMD3100 combination investigated here, was
more effective than either individual treatment, but the
benefits of combined VEGF–G-CSF therapy were not
observed in a subsequent clinical trial, despite significant
increases in circulating progenitor-cell counts (2). Although
this relatively small clinical study may have lacked the
statistical power or endpoints needed to establish efficacy,
the authors suggested that adding local SDF-1 administra-
tion to the VEGF–G-CSF combination may increase the
recruitment of mobilized cells to the ischemic tissue and
improve patient outcomes. Both VEGF and SDF-1 are
up-regulated by Shh (4), so the phShh-AMD3100 combi-
nation likely harnesses many of the same signaling pathways
that would be triggered by a 3-component combination of
VEGF, SDF-1, and G-CSF, as well as the angiogenic and
cytoprotective mechanisms activated by the Shh-induced
up-regulation of angiopoietin and insulin-like growth
factor-1 (4). Furthermore, AMD3100 rapidly mobilizes
progenitor cells after a single administration and, conse-
quently, may be more suitable for clinical use than G-CSF,
which must be administered repeatedly over several days.
Use of G-CSF may also increase the risk of restenosis (3),
and a recent meta-analysis found no evidence of func-
tional improvement with G-CSF–induced cell mobiliza-
tion alone (8).
Because Shh regulates the expression of numerous angio-
genic factors, the beneficial effects of Shh-AMD3100 com-
bination therapy likely evolve through several mechanisms.
BMPC recruitment was higher in animals treated with
combination therapy than in other treatment groups, and
our in vitro results suggest that this enhancement may have
been caused by increased expression of SDF-1 from cardiac
fibroblasts, which are the most common cells in infarcted
myocardium. Local SDF-1 expression is required for
progenitor-cell recruitment after MI (11,12), and SDF-1
overexpression improves progenitor-cell homing (13); how-
ever, SDF-1 administration alone may not sufficiently
enhance cell incorporation (13), so the Shh-induced up-
regulation of other factors, including VEGF, may also
contribute to progenitor-cell incorporation. Furthermore,
Shh-conditioned media enhanced migration, proliferation,
and tube formation in BMPCs, and migration in endothe-
lial cells, so the angiogenic potential of incorporatedBMPCs and locally resident endothelial cells may also be
increased by combination therapy.
Investigations into the role of the SDF-1/CXCR4 axis
during recovery from myocardial injury have yielded appar-
ently conflicting results. Proulx et al. (14) have linked
AMD3100 administration to reductions in infarct size and
improved systolic function, whereas reports by Askari et al.
(11) and Yamaguchi et al. (12) suggest that the interaction
between SDF-1 and CXCR4 contributes to ischemic tissue
repair. Notably, the plasma half-life of AMD3100 (2 to 3 h)
indicates that the direct effects of AMD3100-induced
CXCR4 blockade will dissipate within a day of administra-
tion, whereas the enhanced BMPC mobilization triggered
by AMD3100 endures for days or weeks (15), and combi-
nation therapy enhanced SDF-1 expression in the infarcted
and border-zone regions on day 5 after infarction. Further-
more, AMD3100 has been linked to up-regulated VEGF
and MMP-9 expression in BMPCs (15), which suggests
that AMD3100 is not simply a CXCR4 antagonist; rather,
it appears to possess certain agonist properties, and conse-
quently, the benefits associated with AMD3100 adminis-
tration cannot be exclusively attributed to declines in SDF-1
activity. Thus the acute effects of AMD3100 could increase
the number of BMPCs released from the bone marrow by
disrupting the SDF-1/CXCR4 axis, whereas the long-term
effects of AMD3100 and Shh could increase the incorpo-
ration of the mobilized cells by elevating the expression of
angiogenic cytokines in BMPCs and enhancing SDF-1
expression in ischemic tissue.
Recent experiments performed by Jujo et al. (15) indicate
that AMD3100 does not enhance BMPC mobilization in
MMP-9 knockout mice and that the benefit of treatment
with AMD3100 alone after MI requires MMP-9 expression
in bone marrow cells, but not in the ischemic region.
Furthermore, MMPs are believed to promote cell migration
(16) by degrading type IV collagen in the basement mem-
branes of vessels and the extracellular matrix (17), and Xiang
et al. (18) have linked improvements in vascularity and
cardiac recovery after surgical MI in rats to increases in
BMPC trans-endocardial migration. Thus MMP-9 likely
mediates the benefit of combination therapy both by facil-
itating AMD3100-induced BMPC mobilization and by
improving BMPC migration. The potential relationship
between MMP-9 and SDF-1 expression also warrants
continued investigation.
Conclusions
Our findings demonstrate that combination therapy
consisting of intramyocardial Shh gene transfer and
AMD3100-induced progenitor-cell mobilization improves
cardiac functional recovery after MI and is superior to either
individual treatment for promoting therapeutic neovascular-
ization. Thus this therapeutic combination may prove to be
a viable treatment for a variety of ischemic diseases.
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For an expanded Methods section and supplementary figures and table,
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